CrystalForms@Bologna 2021 - online meeting - Provisional Programme

 

Friday 10 September

9:30-9:40

Opening of the Event, Dario Braga, MCE lab, University of Bologna

9.40-10.00

Solubility and Permeability Issues in Drug Solid Forms, Gautam R. Desiraju, Indian Institute of Science

10.00-10.20

The Search for Polymorphs of a Prolific Solvate Former, Galunisertib, Susan Reutzel-Edens, Cambridge Crystallographic Data Centre, UK

10.20-10.40

Comparing nucleation and growth rates of molecular crystals, Roger Davey, University of Manchester, UK

10.40-11:20

discussion and coffee

11.20-11.40

Behind the paper - analysis of metastable pharmaceutical loratadine form II, Grahame R Woollam, Associate Director Data Science Scientific Lead, Solid-State Chemistry API Modelling & Particle Engineering Novartis Campus, Basel - Switzerland

11.20-12.40

On the entropy cost of solvates, Alessia Bacchi, Dipartimento SCVSA - University of Parma, Italy

11.40-12.00

Living with the Risk for Crystallisation in the case of Amorphous Formulations, Aerts Luc, UCB Pharma, Belgium

12.00-12.20

Polymorphism and selectivity in inclusion compounds Susan Bourne - University of Cape Town, South Africa

12.20-13.00

discussion

13.00-14.00

lunch break & flash presentations

14.00-14.20

Investigation of nanocrystalline and amorphous organic compounds using pair-distribution functions, Martin Schmidt, Goethe University Frankfurt Institute of Inorganic and Analytical Chemistry, Germany

14.20-14.40

NMR tools for the characterization of pharmaceutical crystal forms, Michele Chierotti, Department of Chemistry, University of Torino, Italy

14.40-15.00

APIs' polymorphism and other issues, Enrico Modena, PolyCrystalLine s.p.a., Italy

15.00-15.20

The thin line between polymorphism and solid-solutions, Aurora Cruz Cabeza, University of Manchester, UK

15.20-16.00

discussion & coffee

16.00-16.20

Use of Crystal Structures in the Pharmaceutical Industry, Helen Blade, Associate Principal Scientist – Structural Science, AstraZeneca, Oral Product Development, Pharmaceutical Technology & Development, Operations, Macclesfield, UK

16.20-16.40

Crystal Engineering applied to enantiomeric resolution of racemic Fluoxetine, Javier Alcides Ellena, Sa~o carlos Institute of Physics, University of Sa~o Paulo, Sa~o Carlos, SP - Brazil

16.40-17.00

Mechanisms of Powder Caking from the Solid State Perspective, Ana Kwokal, SYNGENTA, Jealott's Hill Bracknell, Berkshire, RG42 6EY, UK

17.00-17.20

Mechanochemical and Tribochemical Synthesis of Pharmaceutical Molecules and Solid Forms, Tomislav Friscis, McGill University, Canada

17.20-18.00

discussion & drink

18.00-19.00

Gold Sponsors session:

Thermo Fisher Scientific Inc. (NYSE: TMO), Polymorphic Characterization of compounds using XRD and Raman Spectroscopy, Raphael Yerly, Product Manager XRD & Bruno Beccard, European Product Specialist Raman, Microscopy & Hi End Infrared

SPINOFRIN, Spray Flash Evaporation : An efficient process to engineer submicron Active Pharmaceutical Ingredients
Authors : Pierre Le Blainvaux, Jean-Baptiste Coty, Ilaria Ferrando, Ce´dric Martin, Isabella Telo`, Denis Spitzer , Speaker : Denis Spitzer

NETZSCH Geraetebau GmbH

19.20-20.00

flash presentations, poster session and aperitif


 

Complete Programme CF@BO 2021

Saturday 11 September

9:00-9:20

Crystal Engineering of Solid-state Pharmaceuticals: From Synthons to Salt-Cocrystal Drugs, Ashwini K. Nangia, School of Chemistry, University of Hyderabad, India

9:20-9:40

News about the solid form landscapes of co-formers, Doris Braun, University of Innsbruck, Institute of Pharmacy, Austria

9:40-10:00

Cocrystals then and now, Mike Zaworotko, Bernal Institute, University of Limerick, Ireland

10:00-10:20

Cocrystal, ionic cocrystal and corresponding salts, Nicholas Blagden, University of Lincoln, UK

10:20-11:00

discussion & coffee

11.00-11.20

The commercialisation conundrum, when a molecule has a hydrated solid form, Pat Basford, Senior Principal Scientist, Pfizer R & D UK Ltd

11.20-11.40

Mechanochemical reactivity inhibited, prohibited and reversed by liquid additives, Bucar Kreso, Department of Chemistry at University College London in London, UK

11.40-12.00

Elusive predicted polymorphs - industrially relevant or not ?, Philipp Ectors, Solid State Sciences - Particle Design, Pharma Technical Development Synthetic Molecules, F. Hoffmann-La Roche Ltd, Switzerland

12.00-12.20

A tautomer in my tablet!: Occurrence and implications, Amy Woods-Ryan, The University of Manchester and GSK, UK

12.20-13.00

discussion

13.00-14.00

lunch break and flash presentation

14.00-14.20

Why don’t we find more polymorphs?, Sarah (Sally) L Price FRS, University College London, UK

14.20-14.40

Not just polymorphism: The particle size as API CQA for drug product development, Matteo Daldosso, Aptuit, an Evotec Company, Italy

14.40-15.00

Polymorphism of Sugars and the Use of Optical Rotation for the Detection of Crystalline Forms, Martin Viertelhaus, BASF SE, Advanced Materials & Systems Research, Germany

15.00-15.20

Mechanochemistry and Crystal Engineering: a toolbox for enhancing pharmaceuticals properties, M. Teresa Duarte, Instituto Superior Te´cnico, Portugal

15.20-16.00

discussion & coffee

16.00-16.20

Extraordinary Mechanical Properties of Organic Crystals and Implications for Solid Dosage Formulations,Panc?e Naumov, New York University / New York University Abu Dhab, USA

16.20-16.40

Preferential cocrystallization for the resolution of drug compounds, Tom Leyssens, UCLouvain, Belgium

16.40-17.00

Unraveling complexity in the development of a hydrate form: a scientific journey from molecule to crystal to medicine, Alessandra Mattei, Principal Research Scientist, AbbVie Inc, USA

17.00-17.20

Using Advanced Crystallization Methods to Fill in the Solid Forms Landscape, Jonathan Steed, Durham University, UK

17.20-17.40

Tackling antimicrobial and anti enzymatic activity via cocrystallization, Fabrizia Grepioni, University of Bologna, Italy

17.40-19.00

discussion and closing remarks


 


Share